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Since the 1960s, renal replacement ther-
apy (RRT) has been used to treat the effects 
for acute renal insufficiency complicating 
major medical, surgical, or obstetric illness. 
In those early days, whether in an intensive 
care unit (ICU) or in a renal ward, RRT was 
invariably provided by renal specialists, re-
flecting the complexity of the dialysis tech-
nology of the time. Over-time, patients with 
acute renal failure in the context of multiple-
organ dysfunction or major nonrenal illness 
were more rarely treated in renal wards, 
however, in many countries, RRT for the 
critically ill has remained prescribed and de-
livered by a nephrology service visiting the 
ICU. In other locales, including the United 
Kingdom, provision of RRT within the ICU 
has instead become the near-exclusive pre-
serve of the intensive care specialist, deliv-
ered by ICU nursing staff with no require-
ment for specialist renal input or even the 
presence of a renal service in the hospital. 
The history of this change is interesting: In 
major UK hospitals in the 1970s, RRT in the 
form of hemodialysis or peritoneal dialysis 
(PD) was provided by the nephrology team 
to all patients, including those requiring me-
chanical ventilation in ICU [1]. Over-time, 
hemodialysis technology progressed, and by 
the early 1980s arteriovenous hemofiltration 
was being introduced for sicker ICU patients, 
still delivered largely by nephrologists [1]. 
Two things then occurred in the mid 1980s, 
firstly there was a significant expansion of 
the end-stage renal failure population with a 
five-fold increase in the UK chronic dialysis 
population from 1982 to 2002, shifting the 
focus of renal services to the management 
of CKD centralized in large regional renal 
units and away from acute renal failure. Sec-
ondly, around the same time, the introduc-
tion of microprocessor-controlled pumped 
veno-veno continuous renal replacement 
therapy (CRRT) devices greatly facilitated 
and simplified prescription and delivery of 
RRT to the sickest of patients. In the UK and 
Australia, the adoption of CRRT technolo-
gies was led by intensivist [2]. As a result, 
by the early 2000s, CRRT was the mainstay 
of therapy being used in > 90% of UK ICUs, 
solely under the direction of the intensivist 
in 89% of ICUs [3], and, by 2008, CRRT in-
termittent hemodialysis was only available at 
all in 10% of UK ICUs and rarely employed 
in those where it was technically available 
[4]. Thus, the UK provides a specific view-
point to consider the benefits and drawbacks 
of the intensivist-led RRT provision for the 
critically ill.
The benefits and disadvantages 
of intensivist-led RRT in the 
critically ill
Intensivist-led provision of RRT involves 
the decision to commence, and all aspects 
of, RRT prescription being made by the at-
tending intensivist with by line insertion and 
delivery of therapy by the ICU medical and 
nursing staff. This is the standard model of 
practice in countries such as the UK, Austra-
lia, and Sweden. The major advantage of this 
approach is that RRT just becomes another 
form of organ support applied by the ICU 
team to critically ill patients with multiple-
organ failure. Thus, when RRT is clinically 
indicated, therapy can commence rapidly 
without additional consultation or the atten-
dance of an external renal nurse. Importantly, 
RRT prescription can be integrated into a pa-
tients’ hemodynamic, respiratory, nutritional, 
and pharmacological management, all coor-
dinated by the intensivist. Furthermore, RRT 
can then be adjusted immediately to acute 
changes in clinical condition and integrated 
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with other organ support by the bedside ICU 
medical and nursing team. While early com-
mencement of RRT based on levels of serum 
creatinine is not clearly beneficial [5], serum 
creatinine is unlikely to be the best marker of 
the acute imbalance between renal functional 
capacity and the demand for renal function 
in critical illness. It is likely that prompt in-
stitution of RRT is beneficial in those with 
inadequate renal function in the context of 
their illness and its treatment [6], an evalua-
tion that the intensivist, with a global view of 
the patient’s critical illness, is best placed to 
make. Finally, provision of RRT in the ICU 
by intensivists and ICU nurses naturally fa-
vors the use of continuous modalities in step 
with the continuous nature of other organ 
support provided in the ICU. While defini-
tive trial-evidence is of its superiority is lack-
ing [7], the use of CRRT is recommended in 
hemodynamically unstable patients needing 
RRT [8] (the majority of those in the ICU). It 
is less associated with development of fluid 
overload [9] and is associated with better 
long-term outcomes in epidemiological stud-
ies [10]. Conversely, CRRT may be more 
difficult to implement by a visiting renal ser-
vice both from a cost, human resources, and 
ease-of-prescribing point of view, leading to 
a potential bias toward use of intermittent he-
modialysis (IHD).
While there are many potential benefits 
of embedding RRT provision within the ICU 
team, several disadvantages exist. In order to 
deliver safe and effective therapy by a broad-
based clinical team without nephrologist in-
put, in most ICUs, RRT is restricted to the 
sole use of continuous therapies with relative-
ly inflexible protocols optimized toward the 
treatment of the sickest patients. While this 
is ideal for the management of early critical 
illness, continued use of conventional CRRT 
over many weeks of a prolonged recovery in 
the ICU may be more labor intensive, costly, 
and can restrict opportunities for rehabilita-
tion. The flexibility to provide intermittent 
or extended intermittent treatment to these 
patients is a potential advantage of a special-
ist renal service. Other patient groups may 
also benefit from better-tailored prescription 
and wider modality choice, in particular pa-
tients with preexisting end-stage renal dis-
ease (ESRD) requiring ICU admission, and 
in circumstances where rapid clearance of a 
exogenous dialyzable toxin or resolution of 
an extreme electrolyte abnormality (such as 
profound hyperkaliemia) would benefit from 
the greater efficiency of online hemodialysis. 
Finally, the ease of institution of RRT in an 
intensivist-led model does run the risk that 
RRT may be implemented at too low a clini-
cal threshold with the potential for increased 
cost and patient harm from unneeded treat-
ment; in this context, the hand of an external 
nephrology consultation may be advanta-
geous in tempering therapeutic overenthusi-
asm.
Other benefits from the involvement of a 
renal specialist may accrue that are not di-
rectly linked to the provision of RRT. For 
instance, cases of intrinsic renal disease pre-
senting as critical illness, such as systemic 
vasculitis, may be more rapidly recognized 
and treated, and patients with preexisting 
chronic kidney disease or those developing 
CKD after RRT-requiring AKI can be seam-
lessly followed up and managed by the same 
service after ICU discharge and as outpa-
tients. In the UK, patients requiring RRT in 
the ICU without previous renal history are 
rarely followed up, despite evidence of sig-
nificant progression of CKD in this popula-
tion [11], providing a significant challenge 
for intensivist-led care. However, while 
nephrology-led acute-RRT services provide 
the opportunity to achieve follow-up, this 
does not mean that this actually occurs [12] 
– too often the attitude amongst physicians 
has been that dialysis independence means 
continued nephrology involvement is no lon-
ger required, despite this being of significant 
potential benefit [13].
Given the pros and cons of these inten-
sivist- and nephrologist-led approaches (Ta-
ble 1), what is the optimum model for RRT 
provision in the critically ill? In my opinion, 
critically ill patients are united by severity of 
disease and the interplay of multiorgan dys-
function, and the ability to rapidly commence 
RRT and integrate therapy with demands of 
acute critical illness are the key features fa-
voring embedding RRT provision within the 
ICU. However, no studies have compared 
organization of service provision for RRT 
in the ICU. Observational reports examining 
the transition from IHD toward CRRT in the 
early 90s suggested significant benefit [14], 
but these were not sustained in the highly-
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Table 1. 
Acute RRT providers Intensivist/ICU nurse Nephrologist/renal nurse
Timing Rapidly after decision to initiate Potentially delayed, requiring external consulta-
tion and nurse
Modality Largely continuous with transition to IHD in ICU 
often not possible
Potentially biased against continuous therapy
Cost High consumables with CRRT vs. IHD, but 
potentially lower nursing and physician costs 
using existing ICU resources
Lower consumables with IHD vs. CRRT, but 
potentially higher nursing and physician costs
“Integration with other” 
therapy
Well integrated with respiratory and hemody-
namic management in multiorgan failure
Requires multi-professional team-working to inte-
grate RRT into other aspects of critical illness
Individualized therapy Simple, but inflexible protocols, well optimized 
for treatment in acute critical illness, but less 
suited to the recovery phase and for existing 
ESRD patients
Ability and expertise to tailor therapy to unusual 
clinical situations,
facilitates management of the ESRD patient in 
the ICU.
Renal follow-up Often neglected, 
 requires renal consultation
Can be seamlessly continued after ICU 
discharge, 
new referral not required
CRRT = continuous renal replacement therapy; ESRD = end-stage renal disease; ICU = intensive care unit; IHD = intermittent hemo-
dialysis; RRT = renal replacement therapy.
Table 2. Comparison of results and therapy in the VA/NIH ATN study and RENAL studies where similar 
groups of critically ill patients with AKI were treated in the USA and Australia & New Zealand, respec-
tively [15, 16, 17].
VA/NIH ATN study (USA) RENAL study (Aus & NZ)
Number 1,124 1,465
Age, years 59.7 64.5
Percentage of males 70.6% 64.6%
CKD classification (of those with known eGFR)
 0 – 2 65.5% 42.0%
 3a 22.7% 17.9%
 3b 11.9% 19.2%
 4 Excluded 20.9%
 5 Excluded Excluded
Sepsis 63.0% 47.9%
Mechanical ventilation 80.6% 73.9%
Illness-severity score APACHE II: 26 APACHE III: 102.4
Cardiovascular SOFA 2.3 2.9
Modalities of RRT CVVHDF, SLEDD, or IHD CVVHDF
Commenced on CRRT 69.7% 100%
IHD in ICU at any time 63.1% 7.3%
Time from ICU admission to RRT 6.7 days
(3.2 days from AKI diagnosis) 2.1 days
Urea at study enrolment 23.8 mmol/L 23.5 mmol/L
Survival at day 60 47.4% Not reported
Survival at day 90 Not reported 55.3%
Alive and off RRT
 At day 28 25.8% 45.9%
 At day 60 16.1%* Not reported
 At day 90 Not reported 47.7%
*Discharged alive off RRT. APACHE = Acute Physiology and Chronic Health Evaluation; CKD = chronic 
kidney disease; CRRT = continuous renal replacement therapy; ICU = intensive care unit; IHD = intermit-
tent hemodialysis; RENAL = Randomized Evaluation of Normal vs. Augmented Level; RRT = renal re-
placement therapy; SOFA = Sequential Organ Failure Assessment; VA/NIH ATN = Veterans Affairs/Na-
tional Institutes of Health Acute Renal Failure Trial Network.
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selected patients randomized to trials exam-
ining intermittent vs. continuous modality. 
Some insights can be gained by examining 
the two largest randomized trials conducted 
to date examining RRT provision in the ICU, 
the VA/NIH ATN study [15] and the RENAL 
study [16]. These studies were respectively 
conducted in the USA and Australia & New 
Zealand where there were significant dif-
ferences in practice of RRT management in 
the ICU, with predominantly intensivist-led 
treatment and 100% first use of CRRT in 
Australia & New Zealand, compared to a 
significant reliance on nephrology-delivered 
IHD in the USA. Thus, even though their 
primary clinical question regarding intensity 
of RRT was negative, interesting inferences 
can be gathered by comparing overall out-
comes in the two studies. Despite compara-
ble illness severity, level of uremia, and age, 
long-term survival free from chronic dialy-
sis was much more common in the  RENAL 
compared to the ATN study, 48 vs. 16% 
(Table 2). The major differences between 
these studies (Table 2) were more swift com-
mencement of RRT from time of ICU admis-
sion and much lower exposure to IHD at any 
point in the ICU stay in the RENAL study 
(7 vs. 63%). While it is tempting to conclude 
that intensivist-led management led to the 
superior outcomes in the RENAL study, it 
is also possible that the renal specialists in-
volved the ATN study were more selective 
at screening out patients who would survive 
without RRT, the group that have the best 
outcomes. Overall, side-by-side compari-
sons of these approaches are unlikely to be 
feasible as organization of RRT provision in 
the ICU is only one manifestation of differ-
ences in ICU culture between healthcare set-
tings. However, this comparison does at least 
suggest that wider use of CRRT and earlier 
use in those with clinical indications may be 
features of an intensivist-led model, which 
could be most beneficial to patients.
Conclusion
In 2017, models of care in the best in-
stitutions around the world are no longer at 
the extremes discussed above. In the UK, 
intensivists with specialist renal interest and, 
not uncommonly, joint specialist training in 
nephrology are able to provide clinical ex-
pertise, devise more flexible RRT protocols, 
and provide liaison with specialist renal 
services without compromising speed and 
integration of RRT into integrated organ sup-
port. Similarly, in nephrology-led care, renal 
specialists are becoming more subspecial-
ized, with acute nephrology physicians and 
nurses having a much greater presence in the 
ICU and integration with the ICU team dur-
ing the management and follow-up of criti-
cally ill patients with advanced AKI. Thus, 
the answer to the challenges of performing 
best-quality RRT in the ICU may not be not 
to promote an exclusively intensivist- or ne-
phrologist-led approach, but to take the best 
from each model into one’s current practice 
with the aim of providing the best “critical 
care nephrology” service to our patients.
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